Skip to main content
. 2020 May 20;12(5):1294. doi: 10.3390/cancers12051294

Table 2.

Clinicopathological analysis and patient survival.

Pathological Findings Comparison Number (of Patients) Median Survival (Months) p-Value
Differentiation Well: mod-poor 081:155 21:17 0.0005
Invasion
…to bile duct (CH) −ve: +ve 133: 103 20:16 0.027
…to duodenum (DU) −ve: +ve 163: 073 21:13 0.005
…to front constructs of pancreas (S) −ve: +ve 127: 109 22:14 0.001
…to back constructs of pancreas (RP) −ve: +ve 078: 158 29:15 ≤0.001
…to portal vein (PV) −ve: +ve 172: 064 22:11 ≤0.001
…to artery (A) −ve: + ve 222: 014 19:09 0.003
…to peripancreatic neuroplexus (PL) −ve: + ve 167: 069 23:11 ≤0.001
…to the other organs (OO) −ve: + ve 223: 013 18:12 0.011
…to lymph duct in the pancreas (Ly) ≤1: ≥1 162:074 22:12 ≤0.001
…to vein in the pancreas (V) ≤1: ≥1 095: 141 27:14 0.002
…to nerve in the pancreas (Ne) ≤1: ≥1 076: 160 29:15 ≤0.001
…to main pancreatic duct (Mpd) −ve: + ve 124:112 21:16 0.317

Pathological findings including invasion to different parts of the pancreas were analyzed to determine median survival time (MST) and grades of PDAC. p ≤ 0.05 were considered significant.